Drug Approval | November 10, 2025
Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Subscribe To Our Newsletter & Stay Updated
